Are glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson’s disease (PD). Does the clinical trial with lixisenatide add anything?

Are glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson’s disease (PD). Does the clinical trial with lixisenatide add anything?

Source: Physician's Weekly

Parkinson's disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.A phase 2 clinical trial of lixisenatide, a GLP-1 receptor agonist, in the early stages of PD. The primary endpoint was the MDS-UPDRS part 3 motor change in score

Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.
A phase 2 clinical trial of lixisenatide, a G… [1032 chars]

Read more